Publications
(2026) An allosteric network governs Tom70 conformational dynamics to coordinate mitochondrial import. Structure. 34, 273-283.e6
(2026) An allosteric network governs Tom70 conformational dynamics to coordinate mitochondrial import. Structure. 34, 273-283.e6
(2026) Benzoxaborole-modified azithromycins inhibit translation without inducing expression. Antimicrob Agents Chemother. 10.1128/aac.01539-25
(2026) Discovery and development of potent and selective dual NUAK/MARK inhibitors as Hippo pathway modulators for the treatment of cancer. Eur J Med Chem. 311, 118798
(2026) Discovery and Optimization of a Potent, Efficacious, and Brain-Penetrant Inhibitor of KRAS G12C. J Med Chem. 69, 5241-5258
(2026) Discovery and Optimization of a Potent, Efficacious, and Brain-Penetrant Inhibitor of KRAS G12C. J Med Chem. 69, 5241-5258
(2026) Discovery of a Potent, Selective, and In Vivo Efficacious Covalent Inhibitor for Lysine Methyltransferase SETD8. J Med Chem. 69, 4255-4269
(2026) Dual recruitment of two CCM2 molecules to KRIT1 suppresses KLF4 expression. Nat Commun. 10.1038/s41467-026-69595-7
(2026) Serendipitous Discovery of an Allosteric Inhibitor Binding Groove in the Proline Biosynthetic Enzyme Pyrroline-5-Carboxylate Reductase 1 (PYCR1). Biochem J. 10.1042/BCJ20250278
(2026) Small-molecule binding and sensing with a designed protein family. Nat Commun. 10.1038/s41467-026-70953-8
(2026) Tetravalent antibodies are more potent and efficacious erythropoiesis-stimulating agents than erythropoietin in vivo. Protein Sci. 35, e70462
(2026) Tetravalent antibodies are more potent and efficacious erythropoiesis-stimulating agents than erythropoietin in vivo. Protein Sci. 35, e70462
(2025) Allosteric inhibition of JAK2 with lysine-reactive compounds that bind the pseudokinase domain. Eur J Med Chem. 302, 118274
(2025) An asymmetric tetrabody is a potent and efficacious agonist of the erythropoietin receptor in vitro and in vivo. Protein Sci. 34, e70292
(2025) An asymmetric tetrabody is a potent and efficacious agonist of the erythropoietin receptor in vitro and in vivo. Protein Sci. 34, e70292
(2025) An asymmetric tetrabody is a potent and efficacious agonist of the erythropoietin receptor in vitro and in vivo. Protein Sci. 34, e70292
(2025) BBO-10203 inhibits tumor growth without inducing hyperglycemia by blocking RAS-PI3Kα interaction.. Science. 10.1126/science.adq2004
(2025) BBO-10203 inhibits tumor growth without inducing hyperglycemia by blocking RAS-PI3Kα interaction.. Science. 10.1126/science.adq2004
(2025) BBO-10203 inhibits tumor growth without inducing hyperglycemia by blocking RAS-PI3Kα interaction.. Science. 10.1126/science.adq2004
(2025) Bi-allelic PRMT9 loss-of-function variants cause a syndromic form of intellectual disability. Am J Hum Genet. 10.1016/j.ajhg.2025.10.014
(2025) Bi-allelic PRMT9 loss-of-function variants cause a syndromic form of intellectual disability. Am J Hum Genet. 10.1016/j.ajhg.2025.10.014
(2025) Bi-allelic PRMT9 loss-of-function variants cause a syndromic form of intellectual disability. Am J Hum Genet. 10.1016/j.ajhg.2025.10.014
(2025) Bi-allelic PRMT9 loss-of-function variants cause a syndromic form of intellectual disability. Am J Hum Genet. 10.1016/j.ajhg.2025.10.014
(2025) Bi-allelic PRMT9 loss-of-function variants cause a syndromic form of intellectual disability. Am J Hum Genet. 10.1016/j.ajhg.2025.10.014
(2025) Bi-allelic PRMT9 loss-of-function variants cause a syndromic form of intellectual disability. Am J Hum Genet. 10.1016/j.ajhg.2025.10.014

